Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Sold Rep. David Taylor

Key Points

• Rep. David Taylor sold between $1,001 and $15,000 of Vertex Pharmaceuticals stock on August 26, according to a September 5 disclosure. He also sold shares of Amgen and Microsoft while purchasing stakes in Fifth Third Bancorp, Broadcom, and American Electric Power.
• Vertex shares opened at $546.12, near their 52-week high of $560.25. The company’s latest quarterly revenue rose 12.5% year over year to $3.33 billion, though earnings per share of $4.73 narrowly missed estimates.
• Analysts maintain a generally positive outlook, with Vertex carrying a “Moderate Buy” consensus rating and an average price target of $569.52. Institutional investors own approximately 90.96% of the company’s stock.

Representative David Taylor (Republican-Ohio) recently sold shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Vertex Pharmaceuticals stock on August 26th. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)" account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Amgen NASDAQ: AMGN on 8/26/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Fifth Third Bancorp NASDAQ: FITB on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of American Electric Power NASDAQ: AEP on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/14/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/11/2026.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/11/2026.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/11/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 7/24/2026.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $546.12 on Tuesday. The stock has a market capitalization of $138.61 billion, a PE ratio of 31.79, a P/E/G ratio of 2.37 and a beta of 0.32. The company's fifty day moving average is $510.43 and its 200 day moving average is $471.81. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $374.17 and a fifty-two week high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 EPS for the quarter, missing analysts' consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.The business had revenue of $3.33 billion during the quarter, compared to analysts' expectations of $3.23 billion. During the same period in the previous year, the business earned $4.52 earnings per share. The business's quarterly revenue was up 12.5% on a year-over-year basis. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.88 earnings per share for the current year.

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Summit Global Investments purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $3,568,000. Allworth Financial LP increased its position in shares of Vertex Pharmaceuticals by 414.1% during the fourth quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company's stock worth $6,363,000 after acquiring an additional 11,306 shares during the period. Calamos Advisors LLC increased its position in shares of Vertex Pharmaceuticals by 77.1% during the first quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company's stock worth $34,779,000 after acquiring an additional 33,917 shares during the period. Meiji Yasuda America Inc bought a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $1,911,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its stake in shares of Vertex Pharmaceuticals by 11.9% during the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company's stock valued at $15,625,000 after acquiring an additional 3,710 shares in the last quarter. Institutional investors own 90.96% of the company's stock.

Analysts Set New Price Targets

VRTX has been the topic of several analyst reports. Royal Bank Of Canada boosted their price objective on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 7th. Weiss Ratings cut Vertex Pharmaceuticals from a "buy (b)" rating to a "buy (b-)" rating in a report on Tuesday, August 25th. The Goldman Sachs Group set a $653.00 target price on Vertex Pharmaceuticals in a research report on Tuesday, September 1st. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, July 29th. Finally, Barclays raised their price target on Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $569.52.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 1,500 shares of the company's stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the sale, the executive vice president directly owned 45,321 shares in the company, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 4,062 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $450.00, for a total value of $1,827,900.00. Following the transaction, the chief marketing officer directly owned 16,953 shares in the company, valued at $7,628,850. The trade was a 19.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,719 shares of company stock valued at $4,174,147 over the last quarter. 0.20% of the stock is owned by corporate insiders.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.